The newer, supposedly safer atrial fibrillation (Afib) ablation systems had safety issues of their own, researchers reported ...

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

Ablation of the posterior nasal nerve leads to durable reductions in symptoms of chronic rhinitis, new research shows.

NeuroOne submits FDA filing early for trigeminal nerve ablation using its OneRF system as the facial pain market sees projected growth to $416 million by 2030.

The new facilities are equipped with a state-of-the-art C-arm imaging system, an ultrasound machine, a radiofrequency ...